Business
Strategic partnership with Bened Biomedical
Strategic partnership with Bened Biomedical.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 5525Q OptiBiotix Health PLC 13 September 2017 \n\nOptiBiotix Health plc\n(\"OptiBiotix\" or \"the Company\")\n \nStrategic partnership with Bened Biomedical \n \nOptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, has signed a Memorandum of Understanding (\"MoU\") with Bened Biomedical Ltd., Taiwan (\"Bened\"). The MoU sets the framework for a strategic partnership to explore licensing and sales opportunities and the potential of combining relevant assets, over the next 12 months.\n \nBened Biomedical Co., Ltd., was founded in 2015 as a spin off from National Yang-Ming University (\"NYMU\") by Professor Tsai, Ying-Chieh. Bened is a leading probiotic research and marketing companies in Asia developing microbiome based products for neuropsychological, allergic, immunological, metabolic and aging-related disorders. In the past two years, its flagship psychobiotic PS128® products which help improve mental and emotional health, have been sold through both on-line and off-line channels in more than ten countries, generating revenues in the excess of US$2m.\n \nThe MoU provides a 12 month period to explore opportunities relating to OptiBiotix's cholesterol and blood pressure reducing LPLDL® strain and Bened's PS128®, a psychobiotic that has shown encouraging results in reducing anxiety and depression in animal studies. \n \nThis agreement includes:-\n \n· The potential for Bened to commercialise OptiBiotix's LPLDL® strain in Taiwan, Japan, Korea, and South East Asia\n· The potential for OptiBiotix to commercialise Bened's PS128 strain in Europe and the USA\n· The possibility of combining relevant assets to broaden the commercial offering and global reach\n \nFor OptiBiotix this means:\n \n· Widening OptiBiotix's probiotic portfolio into the area of psychobiotics\n· Entering into the area of the \"Microbiota-Gut-Brain Axis\" where mounting evidence suggests that the microbiome helps shape neural development, brain biochemistry and behaviour\n· Opening commercial routes into Taiwan, Japan, Korea and SE Asia for the Company's choleste...